C3 rs147859257: What Your Genotype Means
The rs147859257 variant is a rare genetic change in the C3 gene that results in a specific amino acid substitution. Research has associated this variant with a significantly increased risk of developing age-related macular degeneration (AMD) and geographic atrophy.
What each genotype means
Typical Macular Risk Profile
You carry two copies of the common A allele for this C3 variant. Research indicates this genotype is not associated with increased complement pathway activation or elevated risk for geographic atrophy and age-related macular degeneration. Your baseline risk for these conditions remains governed by broader lifestyle factors and other common genetic determinants.
Carried by approximately 98% to 99% of individuals of European ancestry and is virtually universal in most non-European populations.
Increased Geographic Atrophy Risk
You carry one copy of the low-frequency C risk allele (p.Lys155Gln) in the C3 gene. Studies show this coding alteration reduces complement factor H regulation, resulting in increased alternative complement pathway activation and significantly higher susceptibility to advanced age-related macular degeneration and geographic atrophy. Because this variant confers risk rather than a definitive diagnosis, regular comprehensive eye examinations are recommended to monitor retinal health.
Carried by approximately 1% to 2% of individuals of European ancestry and is extremely rare in African, Asian, and other non-European ancestral groups.
High Macular Degeneration Predisposition
You carry two copies of the rare C risk allele in the C3 gene. Although extremely uncommon in population cohorts, having two copies is predicted to substantially alter complement regulation and confer a high predisposition to age-related macular degeneration and geographic atrophy. Clinical evidence for homozygosity is very limited due to rarity, so discussing baseline retinal imaging and lifelong eye surveillance with an eye care specialist is advisable.
Found in fewer than 1 in 10,000 individuals across European populations and practically unobserved in other ancestral backgrounds.
Understanding the rs147859257 Variant
The rs147859257 variant is a single nucleotide polymorphism (SNP) located within the C3 gene on chromosome 19. In genetic terms, this variant is characterized by a change in the DNA sequence that leads to a p.Lys155Gln substitution in the resulting protein. This means that at position 155 of the protein chain, the amino acid lysine is replaced by glutamine. Because this change occurs in the coding region of the gene, it is referred to as a nonsynonymous variant. Scientists track this specific location to understand how it might alter the function of the C3 protein and contribute to complex health conditions. It is classified as a low-frequency variant, meaning it is not commonly found in the general population, which makes it a subject of interest for researchers studying the genetic architecture of eye diseases.
The Role of the C3 Gene
The C3 gene provides instructions for making the complement component 3 protein, which is a central player in the human immune system. This protein is a key component of the complement cascade, a complex network of proteins that helps the body clear pathogens, remove damaged cells, and modulate inflammation. The complement system is essential for maintaining homeostasis, but when it becomes overactive or dysregulated, it can cause damage to healthy tissues. In the context of the eye, the C3 protein is involved in the maintenance of the retina. When the C3 protein is altered by variants like rs147859257, it may impair the body's ability to properly regulate the complement pathway. This dysfunction is thought to contribute to the chronic inflammation and tissue degradation observed in conditions like age-related macular degeneration.
Research and Evidence Strength
Scientific research has identified a strong statistical association between the rs147859257 variant and an increased risk of age-related macular degeneration (AMD). Studies, including large-scale sequencing projects, have observed that individuals carrying this variant are more likely to develop advanced forms of AMD, such as geographic atrophy. The evidence suggests that this variant impairs the inactivation of C3b, a byproduct of the complement system, leading to constitutive activation of the alternative complement pathway. While the association is statistically significant, it is important to note that the evidence is considered limited in terms of clinical predictability for any single individual. Genetic risk is only one factor in the development of AMD, which is a multifactorial condition influenced by age, smoking, and other environmental factors. Therefore, the presence of this variant does not guarantee the development of disease.
What This Information Means for You
If you have learned that you carry the rs147859257 variant, it is important to understand that this is a risk factor, not a medical diagnosis. Genetic associations are based on population-level data and cannot predict individual health outcomes with certainty. You cannot change your genetic code, but you can focus on modifiable lifestyle factors that are known to influence eye health, such as maintaining a healthy diet, avoiding smoking, and protecting your eyes from excessive UV exposure. This information should not be used to make medical decisions or to self-diagnose. If you are concerned about your risk for macular degeneration, the most appropriate step is to consult with an ophthalmologist or a genetic counselor. They can provide a comprehensive eye examination and discuss your personal and family history to help you understand your overall risk profile and appropriate screening schedule.
How common is this variant?
The rs147859257 variant is rare, with a minor allele frequency typically reported between 0.5% and 1.0% in European populations.
Frequently asked questions
Does having the rs147859257 variant mean I will get macular degeneration?
No, having this variant does not mean you will develop macular degeneration. It is a risk factor, meaning it is statistically associated with a higher likelihood of the disease, but many other genetic and environmental factors contribute to its development.
What is the C3 gene's function in the eye?
The C3 gene produces a protein that is part of the immune system's complement pathway. In the eye, this system helps maintain retinal health, but if it becomes overactive due to genetic variants, it can contribute to inflammation and tissue damage.
Should I get tested for this variant?
Genetic testing for specific variants like rs147859257 is generally not recommended for the general population. If you have a family history of macular degeneration, you should discuss the utility of genetic testing with an eye care professional or a genetic counselor.
Are there treatments for people with this C3 variant?
Current research focuses on understanding how the complement system contributes to AMD, but there is no specific treatment targeted solely at individuals with this variant. Always discuss any concerns about eye health or potential therapies with your ophthalmologist.
Sources & further reading
Educational information only, last refreshed 10/18/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs147859257?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in C3
This functional coding variant (Arg102Gly) in complement component 3 significantly elevates the risk of developing age-related macular degeneration.
Complement component 3 locus variant identified in genetic association studies of age-related macular degeneration and complement activation.
Variant in complement component 3 associated with altered susceptibility to neovascular age-related macular degeneration.
Complement component 3 variant demonstrating sex-divergent modulation of neovascular AMD susceptibility.